{
  "ticker": "RAD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961383",
  "id": "02961383",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250624",
  "time": "0935",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250624/pdf/06l1hg1m3wpr87.pdf",
  "summary": "**Summary of Material Information:**  \n\n- **Clinical Supply Agreement:** Radiopharm signs agreement with Cyclotek to supply **161Tb-labeled RAD 402** for Phase 1 trial in prostate cancer.  \n- **Trial Timeline:** Ethics approval and Phase 1 trial start anticipated in **2H 2025**.  \n- **Key Preclinical Data:** RAD 402 demonstrates **safety and promising biodistribution**; first company-sponsored Phase 1 trial using **161Tb** for prostate cancer.  \n\n*No material capital markets or trading-impacting updates (e.g., financing, significant dilution, or liquidity events) identified.*",
  "usage": {
    "prompt_tokens": 1518,
    "completion_tokens": 130,
    "total_tokens": 1648,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T23:55:39.951345"
}